Helus Pharma Inc.
HELP
Positions held
Your positionsHELP isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $783.21M | Enterprise value | $616.84M | Trailing P/E | — | Forward P/E | -6.02 |
| PEG | — | Price / book | 2.74 | Beta | 0.54 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -86.9% | ROA | -44.4% | Debt / equity | — |
| Current ratio | 10.97 | Free cash flow | -$82.43M | Analyst recommendation | strong_buy | Mean target | $40.11 |
| 52w high | $15.15 | 52w low | $3.76 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$47.8M | -$47.0M | -$42.7M | -$33.7M | -$24.6M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$49.1M | -$47.9M | -$41.2M | -$28.9M | -$24.6M | — |
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$148M | -$81.6M | -$78.1M | -$47.5M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | $0.0M |
| Operating income | -$143M | -$103M | -$78.8M | -$51.5M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Helus Pharma to Host Investor Presentation on October 21, 2026
2026-10-01 · Helus Pharma Announces Completion of Legal Name Change
2026-09-25 · Cybin (HELP) Stock May Be Trading At A Premium Despite Fresh Depression Trial Data
2026-09-24 · Cybin (HELP) Shares Moved, What Is Behind The Fresh Attention?
2026-09-24 · Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression
2026-09-22 · Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
2026-09-22 · Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board
2026-09-21 · Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
2026-09-21 · Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
2026-09-21 · Cybin Eyes Q4 Phase 3 Data for Depression Drug HLP003
2026-09-21 · Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances
2026-09-10 · Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York
Price (daily)
Full chart · RSI · MACD · patterns